Topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors are novel treatment approaches for atopic dermatitis (AD). This study aimed to compare the efficacy and safety of JAK and PDE4 inhibitors for AD treatment.

To provide an overview of janus kinase (JAK), chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), and phosphodiesterase 4 (PDE4) inhibitors in allergic disorders.

Conclusions and RelevanceThis meta-analysis suggests that topical PDE4 inhibitors are a safe and effective treatment for mild to moderate AD. Current evidence supports the use of …

PDE4 and JAK are two important classes of molecules involved in the inflammatory process of psoriasis, and are viewed as viable targets for psoriasis therapy (15 – 17).

Oct 2, 2021 · Key clinical point: Findings from this network meta-analysis confirm efficacy and safety oftopical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors for atopic dermatitis (AD).

Sep 6, 2021 · This study confirmed that topical JAK and PDE4 inhibitors had promising treatment efficacy and safety for AD patients. Tofacitinib 2% b.i.d., ruxolitinib 1.5% b.i.d. and delgocitinib 3% b.i.d. showed superior efficacy over other JAK and PDE4 inhibitors.

Objective: To provide an overview of janus kinase (JAK), chemoattractant receptor homologous molecule expressed on T H 2 cells (CRTH2), and phosphodiesterase 4 (PDE4) inhibitors in allergic disorders.

The aim of this review was to provide the reader with an overview of PDE4 targeting compounds that have reached clinical trials in the last ten years, since the first PDE4 inhibitor was marketed, with a focus on those most recently developed for respiratory, skin and neurological disorders.

Apr 30, 2023 · Lawrence Eichenfield, MD, spoke in another interview segment with HCPLive on the topic of recent developments in the world of PDE4 and JAK inhibitors for atopic dermatitis (AD). Eichenfield works as chief of pediatric and adolescent dermatology at Rady Children's Hospital in San Diego.

May 1, 2023 · Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference. New insights...